Overview
Hepatitis B virus (HBV) is one of the most common causes of chronic liver disease worldwide. It is a DNA virus belonging to the Hepadnaviridae family and is transmitted mainly through blood exposure, sexual contact, and from mother to child at birth. Clinical presentation varies from subclinical infection to symptomatic hepatitis, and long-term infection can lead to cirrhosis and hepatocellular carcinoma.
Hepatitis B virus shows a high degree of genetic heterogeneity. Based on sequence differences of 8% or more, HBV is classified into ten genotypes, labeled A to J, along with multiple sub-genotypes. Among these, genotypes A, C, and D are the most predominant globally. In India, genotype D is the most prevalent, followed by genotype A, though other genotypes such as B, C, E, F, and G have also been reported.
HBV genotyping plays a crucial role in prognosis, therapeutic decision-making, and epidemiological studies. Along with HBV DNA detection and viral load estimation, genotyping provides valuable insight into disease progression and response to therapy.
Symptoms
Hepatitis B virus infection may remain asymptomatic for long periods, particularly in chronic cases. Many patients are diagnosed incidentally during routine investigations or screening.
When symptoms occur, they are related to hepatitis and may range from mild to severe depending on viral activity and host immune response. In chronic infection, liver damage may progress silently, making laboratory evaluation and genotypic assessment important even in the absence of symptoms.
Causes
HBV infection occurs when blood, semen, or other body fluids from an infected individual enter the body of a non-infected person. Transmission commonly takes place through unprotected sexual contact, sharing needles or syringes, blood transfusions, and vertical transmission during childbirth.
The incubation period ranges from 30 to 180 days. The virus can be detected within 30 to 60 days after infection and may persist, especially when infection occurs in infancy or childhood. Persistent viral replication increases the risk of chronic hepatitis and related complications.
Risk Factors
Certain populations are at higher risk of HBV infection and disease progression. These include healthcare workers, individuals with unsafe sexual practices, injection drug users, recipients of blood products, and newborns of HBV-infected mothers.
Genotype-specific risk factors influence disease severity and outcomes. Some genotypes are associated with prolonged viral replication, delayed seroconversion, and increased risk of cirrhosis and hepatocellular carcinoma. Genotype C, for example, is linked with more severe liver disease compared to genotype B, while genotypes A and B are associated with better treatment response and higher rates of spontaneous seroclearance.
Low viral load, genetic diversity of HBV, and poor sample quality can also affect the accuracy and interpretation of genotyping results.
Prevention
Prevention of HBV infection and its complications relies on early diagnosis, vaccination, safe practices, and appropriate monitoring. HBV genotyping supports prevention strategies by guiding personalized treatment approaches and identifying patients at higher risk of disease progression.
Safe sexual practices, avoidance of needle sharing, screening of blood products, antenatal screening, and universal vaccination are essential preventive measures. In chronic HBV patients, genotyping helps tailor antiviral therapy, predict response to interferon and other treatments, and monitor for resistance mutations.
Genotyping also plays a role in epidemiological surveillance and outbreak investigations by identifying transmission patterns and regional genotype distribution. Combined with HBV DNA testing and viral load monitoring, genotyping contributes significantly to reducing long-term liver complications and improving patient outcomes.
